ContactCredit ReportFinancialsPeopleOwnershipLatest ActivityMutual CompaniesDocumentsRepayment History

Kaerus Bioscience Limited

Kaerus Bioscience Limited is an active company incorporated on 12 July 2016 with the registered office located in . Kaerus Bioscience Limited was registered 9 years ago.
Status
Active
Active since incorporation
Company No
10274924
Private limited company
Age
9 years
Incorporated 12 July 2016
Size
Micro
Turnover is under £1M
Under 10 employees
Confirmation
Submitted
Dated 11 July 2025 (3 months ago)
Next confirmation dated 11 July 2026
Due by 25 July 2026 (9 months remaining)
Last change occurred 2 months ago
Accounts
Submitted
For period 1 Jan31 Dec 2024 (1 year)
Accounts type is Total Exemption Full
Next accounts for period 31 December 2025
Due by 30 September 2026 (11 months remaining)
Address
2nd Floor 168 Shoreditch High Street
London
E1 6RA
United Kingdom
Same address for the past 4 years
Telephone
Unreported
Email
Unreported
Website
Unreported
People
Officers
5
Shareholders
17
Controllers (PSC)
1
Director • Investor • Italian • Lives in Switzerland • Born in Jan 1970
Director • Ceo • American • Lives in United States • Born in Dec 1967
Director • Physician Researcher • American • Lives in United States • Born in Aug 1962
Director • Partner At Medicxi Ventures • Swiss • Lives in Switzerland • Born in Jun 1958
Director • Partner At Medicxi Ventures • American • Lives in United States • Born in Apr 1958
Shareholders, PSCs & Group Structure
See who truly controls a company with full PSC, Shareholder, and Group Structure exploration
Mutual Companies
Levicept Ltd
Francesco De Rubertis is a mutual person.
Active
Ottimo Pharma Limited
Francesco De Rubertis is a mutual person.
Active
Ultrahuman One Limited
Francesco De Rubertis is a mutual person.
Dissolved
Ultrahuman Thirteen Limited
Francesco De Rubertis is a mutual person.
Liquidation
Ultrahuman Fourteen Limited
Francesco De Rubertis is a mutual person.
Dissolved
Ultrahuman Ten Limited
Francesco De Rubertis is a mutual person.
Dissolved
Ultrahuman Nine Limited
Francesco De Rubertis is a mutual person.
Dissolved
Ultrahuman Twelve Limited
Francesco De Rubertis is a mutual person.
Dissolved
Financials
Net Assets, Total Assets & Total Liabilities (2017–2024)
Period Ended
31 Dec 2024
For period 31 Dec31 Dec 2024
Traded for 12 months
Cash in Bank
£2.06M
Decreased by £429K (-17%)
Turnover
Unreported
Same as previous period
Employees
6
Increased by 6 (%)
Total Assets
£2.15M
Decreased by £526K (-20%)
Total Liabilities
-£317K
Decreased by £281K (-47%)
Net Assets
£1.83M
Decreased by £245K (-12%)
Debt Ratio (%)
15%
Decreased by 7.6% (-34%)
Latest Activity
Paul Sekhri Resigned
22 Days Ago on 1 Oct 2025
Full Accounts Submitted
24 Days Ago on 29 Sep 2025
Confirmation Submitted
2 Months Ago on 11 Aug 2025
Mr Francesco De Rubertis Details Changed
3 Months Ago on 11 Jul 2025
Small Accounts Submitted
1 Year Ago on 30 Sep 2024
Confirmation Submitted
1 Year 2 Months Ago on 8 Aug 2024
Dr Howard Mayer Appointed
1 Year 5 Months Ago on 2 May 2024
Marie Henriette Finet Resigned
1 Year 5 Months Ago on 2 May 2024
Paul Sekhri Appointed
2 Years Ago on 6 Oct 2023
Sanford Zweifach Resigned
2 Years Ago on 6 Oct 2023
Get Credit Report
Discover Kaerus Bioscience Limited's Credit Score, how much credit you can offer them, and how likely they are to repay you
Documents
Termination of appointment of Paul Sekhri as a director on 1 October 2025
Submitted on 14 Oct 2025
Statement of capital on 2 October 2025
Submitted on 2 Oct 2025
Resolutions
Submitted on 2 Oct 2025
Solvency Statement dated 30/09/25
Submitted on 2 Oct 2025
Statement by Directors
Submitted on 2 Oct 2025
Total exemption full accounts made up to 31 December 2024
Submitted on 29 Sep 2025
Director's details changed for Mr Francesco De Rubertis on 11 July 2025
Submitted on 12 Aug 2025
Confirmation statement made on 11 July 2025 with updates
Submitted on 11 Aug 2025
Statement of capital following an allotment of shares on 1 October 2024
Submitted on 7 Feb 2025
Accounts for a small company made up to 31 December 2023
Submitted on 30 Sep 2024
Repayment History
Understand how businesses repay their debts and see how they're performing year‐on‐year